The Effects of Alternate-Day Corticosteroids in Autoimmune Disease Patients

• Main Authors: Genny Margarita Chaia-Semerena, María Eugenia Vargas-Camaño, Cesar Daniel Alonso-Bello, Jorge Javier Guillén-Toledo, Ricardo Leopoldo Guido-Bayardo, Fernando Lozano-Patiño, Mariano Daniel Temix-Delfín, María Isabel Castrejón-Vázquez
• Format: Article
• Language: English
• Published: Hindawi Limited 2020-01-01
• Series: Autoimmune Diseases
• Online Access: http://dx.doi.org/10.1155/2020/8719284
• ISSN: 2090-0422; 2090-0430

Introduction. Several studiesdemonstrated that the use of alternate-day corticosteroid therapy maintains control of autoimmune diseases due to the prolongation of their therapeutic effect beyond their metabolic effect, with a significant decrease in side effects in patients. For this reason, the current recommendation for the use of these medications is in a short cycle to avoid adverse effects when used frequently and for prolonged periods of time. Objectives. To learn variations in serum levels of autoantibodies in autoimmune diseases treated with steroids on alternate days, as well as whether there are differences in the response to them depending on the type of disease. Study Design. A descriptive, retrospective, and cross-sectional study was conducted in which serum autoantibody levels were compared at the time of diagnosis and three months after alternate-day corticosteroid therapy. Results. We included 106 patients from three autoimmune connective tissue diseases (systemic lupus erythematosus, Sjögren syndrome, and Hashimoto’s thyroiditis) and observed a statistically significant decrease in serum autoantibody levels both in patients with lupus and those with Hashimoto’s thyroiditis, regardless of the sex of the patients, as well as the type of steroids used. Conclusions. Treatment with alternate-day corticosteroids achieved a statistically significant decrease in serum autoantibody levels in patients with systemic lupus erythematosus and Hashimoto’s thyroiditis.